Format

Send to

Choose Destination
Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.

Author information

1
Division Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
2
Kiromic, Inc., Houston, TX, USA.
3
Department of Otolaryngology (ENT), TTUHSC, Lubbock, TX, USA.
4
CaritasKlinikum Saarbrücken, Saarbrücken, Germany.
5
Department of Multiple Myeloma & Lymphoma, University of Texas, MDACC, Houston, TX, USA.

Abstract

Head and Neck Squamous Cell Carcinoma is a deadly and locally aggressive malignancy that frequently portends a poor prognosis. Since current treatment modalities including surgery, chemotherapy and radiation are heavily debilitating and often result in recurrence intense efforts have been put into the development of novel less toxic and more lasting treatment strategies. Recently, immunotherapy has been proposed as a promising alternative that could potentially meet these requirements. SP17 is a validated cancer-testis antigen in multiple myeloma, ovarian cancer and non-small cell lung cancer. We aim at studying SP17 expression in HNSCC and its immunogenicity as a possible future target for HNSCC therapeutic vaccines. SP17 expression was evaluated in tissue specimens of HNSCC patients and controls. Moreover, SP17 immunogenicity was studied by generating autologous dendritic cells in vitro from the peripheral blood mononucleated cells of HNSCC patients and testing their ability to induce SP17 specific cytotoxic lymphocytes capable of killing autologous tumor cells in vitro. SP17specific immune responses were also evaluated in HNSCC patients as circulating anti-SP17 autoantibodies. SP17 was expressed in HNSCC tissues of HNSCC patients. Autologous dendritic cells pulsed with SP17 antigen induced powerful SP17 MHC class-I restricted, perforin-dependent, cytotoxic T-cells capable of efficiently killing autologous tumor cells in vitro. SP17-specific autoantibodies were detectable in the serum of HNSCC patients irrespective of tumor site or TNM stage. In conclusion, SP17 is an ideal immunotherapeutic target for HNSCC and a potential serological biomarker of the disease.

KEYWORDS:

biomarker; cancer/testis antigens; head and neck squamous cell carcinoma; immunotherapy; sperm surface protein 17

Conflict of interest statement

CONFLICTS OF INTEREST MCI is the CEO and Founder of Kiromic. JAF if Founder and Chief Medical Officer of Kiromic. DDN is Founder and Chief of Clinical Development & Medical Affairs of Kiromic. LM is Executive Director of R&D at Kiromic. All other Authors have nothing to disclose.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center